Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In data presented at the conference, researchers who followed more than 500 patients with type 2 diabetes reported that those taking the highest dose lost an average of about 7.5 kg after nine months
The American Diabetes Association (ADA) has approved tirzepatide as a treatment for adults with type 2 diabetes and obesity
Because gut inflammation is linked to many chronic diseases, this may be one of the mechanisms behind the broader health benefits researchers are seeing
Late escalation (weeks 1316, 1.7 mg): approaching the therapeutic window used in the weight-management trials
Conclusions/interpretation Tirzepatide improves therapeutic target attainment compared with semaglutide in type 2 diabetes
Ground the Lightning
US$ 29.74
US$ 27.90
US$ 26.03
